Merck & Co and Bayer agree their own asset-swapping megadeal
This article was originally published in Scrip
Bayer has won the auction for Merck & Co's consumer care business with a cash offer of $14.2bn. The companies also plan to collaborate in the field of sGC (soluble guanylate cyclase) modulators, for which Merck will make an upfront payment to Bayer of $1bn.
You may also be interested in...
PwC partner Dmitri Drone explained that a deal for an asset with high commercial expectations is best structured with more emphasis on pre-approval than post-approval payments. A post-approval focus on shared risk is more appropriate when an asset is licensed at an earlier stage of development.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.